AstraZeneca Pharma India Signs Healthcare LoI With Reliance's Strand Life Sciences: Shares Gain Post-Announcement

AstraZeneca Pharma India has entered into an LoI with Reliance Industries subsidiary Strand Life Sciences to explore healthcare collaboration opportunities in India. Its shares gained over 2% on the NSE.
AstraZeneca Pharma India has signed a letter of intent (LoI) with Strand Life Sciences Private Limited, a genomics research and diagnostics company owned by Reliance Industries. The regulatory filing dated 17 November 2026 does not specify the proposed collaboration’s scope or the areas in which the companies may work together.
AstraZeneca Pharma clarified that Strand Life Sciences is not a related party and that the LoI does not constitute a related-party transaction.
On the filing date, the AstraZeneca Pharma share price closed at ₹6,168, up 2.24% on the National Stock Exchange (NSE). The stock’s previous close and opening price were both ₹6,033. AstraZeneca Pharma shares touched an intraday high of ₹6,212.50 and a low of ₹5,950.
What Is The AstraZeneca Pharma-Strand Life Sciences Tie-Up About?
The proposed arrangement is aimed at enabling both companies to investigate possible areas of cooperation in the Indian healthcare sector. However, the announcement does not confirm a particular project, commercial arrangement or timeline for implementation.
The company also highlighted its focus on building partnerships across the healthcare ecosystem. It said these efforts are aimed at expanding access to innovative medicines and improving patient outcomes, particularly across oncology, biopharmaceuticals and rare diseases.
AstraZeneca Pharma Q2 FY27 Financials
AstraZeneca Pharma India reported a 14.9% year-on-year (YoY) rise in second-quarter net profit to ₹62.3 crore, compared with ₹54.2 crore in the corresponding quarter of the previous year. Revenue from operations increased 30.4% to ₹729 crore from ₹559 crore.
Earnings before interest, tax, depreciation and amortisation (EBITDA) grew 26.7% to ₹95 crore from ₹75 crore. However, the EBITDA margin moderated to 13.1% from 13.4% a year earlier.
The company attributed its revenue growth to consistent performance across its oncology, biopharmaceuticals and rare disease therapy areas.
For the first half of FY27, revenue from operations stood at ₹1,411.9 crore. This is a growth of around 30% over the same period of the last financial year.
Sources
NSE
Also Read - Metal Stock Surges 17% Near 52-Week High After Major Production and Capex Update; What's Driving the Rally?
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer

Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights










